Urat1 inhibitor, pharmaceutical compositions and uses thereof
US-2024226070-A1 · Jul 11, 2024 · US
US9700517B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9700517-B2 |
| Application number | US-201414470442-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 27, 2014 |
| Priority date | Sep 24, 2009 |
| Publication date | Jul 11, 2017 |
| Grant date | Jul 11, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.
Opening claim text (preview).
The invention claimed is: 1. An acid resistant hard pharmaceutical capsule shell comprising gellan gum and at least one water-soluble film forming polymer, wherein: the weight ratio of gellan gum to said at least one water soluble film forming polymer is between 4/100 to 15/100 parts by weight of gellan gum per 100 parts by weight of the at least one water soluble film forming polymer, wherein the at least one water soluble film forming polymer is selected from the group consisting of hydroxypropyl methyl cellulose; gelatin, pullulan, hydroxypropyl starch, and a mixture thereof, the capsule shell does not comprise additional gelling aids comprising cations, wherein cations are not present in an amount higher than the amount naturally present in the gellan gum, the capsule shell has a moisture content ranging from about 2% to about 16% over the total weight of the shell, and the capsule shell exhibits resistance to leakage of at least 1 hour at pH 1.2 in a USP-30 simulated gastric fluid. 2. An acid resistant hard pharmaceutical capsule comprising a capsule shell comprising gellan gum and at least one water-soluble film forming polymer, wherein: the weight ratio of gellan gum to said at least one water soluble film forming polymer is between 4/100 to 15/100 parts by weight of gellan gum per 100 parts by weight of the at least one water soluble film forming polymer, wherein the at least one water soluble film forming polymer is selected from the group consisting of hydroxypropyl methyl cellulose; gelatin, pullulan, hydroxypropyl starch, and a mixture thereof, the capsule shell does not comprise additional gelling aids, the capsule shell has a moisture content ranging from about 2% to about 16% over the total weight of the shell, and the capsule shell exhibits resistance to leakage of at least 1 hour at pH 1.2 in a USP-30 simulated gastric fluid. 3. The hard capsule according to claim 2 , wherein the capsule shell is filled with at least one substance selected from the group consisting of acid-instable substances and substances associated with gastric side effects in humans and/or animals. 4. A dip-molding process for the manufacture of an acid resistant hard pharmaceutical capsule shell as defined in claim 1 , said process comprising: dipping pins into an aqueous composition comprising gellan gum and at least one water-soluble film forming polymer in a ratio is between 4/100 to 15/100 parts by weight of gellan gum per 100 parts by weight of the at least one water soluble film forming polymer, wherein the at least one water soluble film forming polymer is selected from the group consisting of hydroxypropyl methyl cellulose; gelatin, pullulan, hydroxypropyl starch, and a mixture thereof, wherein the aqueous composition does not comprise additional gelling aids comprising cations, and wherein cations are not present in the aqueous composition in an amount higher than the amount naturally present in the gellan gum; withdrawing the dipping pins from the aqueous composition; and drying the composition adhered on the dipping pins so as to obtain an acid resistant hard pharmaceutical capsule shell that exhibits resistance to leakage of at least 1 hour at pH 1.2 in a USP-30 simulated gastric fluid. 5. A method of administering to a patient at least one substance selected from the group consisting of acid-instable substances and substances associated with gastric side effects, comprising oral administration to said patient of the acid resistant hard pharmaceutical capsule according to claim 2 , comprising the at least one substance. 6. A method of imparting acid resistance properties to a hard capsule shell comprising a mixture of gellan gum, the method comprising: preparing a hard capsule shell from an aqueous composition comprising gellan gum and at least one water-soluble film forming polymer in a ratio is between 4/100 to 15/100 parts by weight of gellan gum per 100 parts by weight of the at least one water soluble film forming polymer, wherein the at least one water soluble film forming polymer is selected from the group consisting of hydroxypropyl methyl cellulose; gelatin, pullulan, hydroxypropyl starch, and a mixture thereof, wherein the aqueous composition does not comprise additional gelling aids comprising cations, and wherein cations are not present in the aqueous composition in an amount higher than the amount naturally present in the gellan gum, and wherein the hard capsule shell prepared from the aqueous composition exhibits resistance to leakage of at least 1 hour at pH 1.2 in a USP-30 simulated gastric fluid.
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Capsules · CPC title
Use of proteins, e.g. casein, gelatine or derivatives thereof, as moulding material · CPC title
Use of polysaccharides or derivatives as moulding material · CPC title
Use of starch or derivatives as moulding material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.